- NeOnc Technologies Holdings, Inc. (NTHI) announced that its **$50 million strategic partnership** with Quazar Investment is mandated to close no later than **October 23, 2025**.  **[1979414_0001829126-25-008052_neonctechnologies_ex99-1.htm:0]** **[1979414_0001829126-25-008052_neonctechnologies_8k.htm:1]** 
- This closing is contingent upon the receipt of all necessary **tax identification and regulatory approvals from the United Arab Emirates (UAE)**, which have now been finalized.  **[1979414_0001829126-25-008052_neonctechnologies_ex99-1.htm:0]** **[1979414_0001829126-25-008052_neonctechnologies_8k.htm:1]** 
- The partnership, centered around the Abu Dhabi-based operating subsidiary NuroCure, aims to launch and scale clinical trials, regulatory filings, and infrastructure development across the UAE and the broader Middle East and North Africa (MENA) region.  **[1979414_0001829126-25-008052_neonctechnologies_ex99-1.htm:0]** 
- The funds will accelerate the development of NeOnc’s therapeutic pipeline, including its **NEO100 and NEO212 clinical programs**, with **$15 million** specifically allocated for Phase 2B clinical trials and infrastructure development in the UAE and MENA.  **[1979414_0001829126-25-008052_neonctechnologies_ex99-1.htm:0]** 
- This transaction will enable NeOnc to initiate **four upcoming clinical trials**: NEO100-01, NEO100-02, NEO212 (all advancing into Phase 2a/2b), and NEO100-03 (its first pediatric brain cancer program entering Phase 1).  **[1979414_0001829126-25-008052_neonctechnologies_ex99-1.htm:0]**

NeOnc Technologies Holdings and Quazar Investment Set to Close $50 Million Strategic Partnership

- NeOnc Technologies Holdings, Inc. (NTHI) received **FDA authorization** on **September 10, 2025**, to proceed with **Phase IIa/IIb of its NEO212-01 clinical trial**.  **[1979414_0001829126-25-007323_neonctechnologies_8k.htm:0]** **[1979414_0001829126-25-007323_neonctechnologies_ex99-1.htm:0]** 
- This authorization follows the **successful completion of the Phase I dose-escalation study**, which demonstrated NEO212 could be safely administered.  **[1979414_0001829126-25-007323_neonctechnologies_ex99-1.htm:0]** 
- NEO212 is a **first-in-class oral chemical conjugated chemotherapy candidate for brain cancer**, which NeOnc believes has the potential to replace Temozolomide (TMZ) as the future standard of care.  **[1979414_0001829126-25-007323_neonctechnologies_ex99-1.htm:0]** 
- Patient enrollment for the Phase II trial is **expected to begin before the end of 2025**.  **[1979414_0001829126-25-007323_neonctechnologies_ex99-1.htm:0]**

NEONC TECHNOLOGIES HOLDINGS (NTHI)